Sorafenib is the first generation of RAF inhibitors, but its clinical efficacy is limited, and it cannot completely inhibit the recurrence of advanced tumours with a high incidence of BRAF mutations, such as melanoma and papillary thyroid cancer (PTC).8, 9. This evidence concerns the gene BRAF and thyroid gland papillary carcinoma.